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Oral candidiasis in HIV+ patients under 
treatment with protease inhibitors
Abstract: The purpose of this work was to evaluate the influence of Pro-
tease Inhibitors (PI) on the occurrence of oral candidiasis in 111 HIV+ 
patients under PI therapy (Group A). The controls consisted of 56 patients 
that were not using PI drugs (Group B) and 26 patients that were not us-
ing any drugs for HIV therapy (Group C). The patient’s cd4 cell counts 
were taken in account for the correlations. One hundred and ninety three 
patients were evaluated. The PI did not affect the prevalence of oral can-
didiasis (p = 0.158) or the frequency of C. albicans isolates (p = 0.133). 
Patients with lower cd4 cell counts showed a higher frequency of C. al-
bicans isolates (p = 0.046) and a greater occurrence of oral candidiasis 
(p = 0.036). 
Descriptors: HIV; Candida albicans; Protease inhibitors.
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Introduction
Oral candidiasis is the most frequent mycosis pro-
duced by yeasts of the genus Candida, Candida albi-
cans being the most important from the point of view 
of Public Health, although other species such as C. 
glabrata, C. parapsilosis, C. tropicalis, C. krusei and 
more recently C. dubliniensis have been isolated.1,2
In the acquired human immunodeficiency syn-
drome (AIDS), it is known that among the oppor-
tunist infections, oral candidiasis is the most fre-
quent one, and C. albicans, among others, has been 
very important in assessing the evolutionary behav-
ior of the disease.3 The first case of acquired human 
immunodeficiency syndrome (AIDS) related in the 
literature mentions that the patient was an oral can-
didiasis carrier.4
In human immunodeficiency virus (HIV+) pa-
tients, nonspecific oral immunity is reduced, con-
tributing to the frequent appearance of candidia-
sis.5,6
One of the most critical factors in the control 
of oral candidiasis in HIV+ patient is the resistance 
that the yeast develops to various drugs, notably 
some of the azolic derivatives.7
The introduction of protease inhibitor (PI) drugs 
on the marketplace for the treatment of AIDS has 
shown promising results in the clinical control of 
the disease, opening up a new perspective in the ef-
forts made to enhance the systemic conditions of 
these patients.8
Many researchers attribute this improvement to 
the increase in the number of cd4 lymphocytes and 
to a reduction in viral load, which restores the pa-
tients’ specific immunity, providing a decline in the 
incidence of opportunistic infections. 
However, HIV virus carriers submitted to treat-
ment with protease inhibitor drugs manifested a de-
cline in oral candidiasis before there was an increase 
in the number of cd4 cells, which has led some au-
thors to believe in the action of these drugs in the 
protease production mechanisms of C. albicans as 
well, leading to a change in its levels of activity.9
The Candida albicans strains isolated from 
HIV+ patients were also those least susceptible to 
the azolic antifungal agents, specifically ketocon-
azol and fluconazol.10
The use of PI in the treatment of patients with 
HIV has diminished the complications related to 
AIDS, such as Kaposi’s sarcoma,11 cryptosporosis12 
and mucosal candidiasis.8,13,14
The PI drugs act directly on the proteases of the 
HIV, making the enzyme inactive, which favors the 
formation of non-infecting viral particles, promot-
ing a reduction in viral load and an increase in cd4 
cells, reestablishing the immune response.15
The antifungal effect of the PIs indinavir and sa-
quinavir were demonstrated in vitro and in vivo.10,16
The aim of this study was to compare the fre-
quency of oral candidiasis in HIV+ patients under 
treatment with protease inhibitor and non protease 
inhibitor drugs.
Material and Methods
One hundred and ninety three HIV+ individuals, 
of both genders, who were having the number of 
cd4 cells assessed at the AIDs home, Zerbini Foun-
dation, São Paulo, SP, Brazil, were selected for this 
study. 
All the patients agreed to participate in the study 
by signing an informed consent form approved 
by the Research Ethics Committees of the School 
of Dentistry, University of São Paulo protocol n. 
18/97), of the AIDS home and of the School of Med-
icine, University of São Paulo.
Group A – 111 patients under treatment with 
protease inhibitors (PI) either associated with 
other drugs or not. 
Group B – 56 patients under treatment with oth-
er non protease inhibitors (NPI).
Group C – 26 patients that were not using medi-
cation for the treatment of AIDS. 
The clinical examination was carried out by a 
single examiner, a specialist in Stomatology, seek-
ing to assess the presence of oral lesions compatible 
with candidiasis. In the cases in which the clinical 
diagnosis was positive, material was collected from 
the lesion for Cytologic testing, using a sterile swab, 
the smears being fixed in alcohol (70%) immediately 
and forwarded to the laboratory for staining (Papa-
nicolaou) and Microscopic examination (200 X). 
Cytologic positivity, combined with a clinical diag-
nosis, confirmed the presence of candidiasis.
•
•
•
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The variables adopted for the present study were 
as follows:
With regard to the presence of oral candidiasis: 
0 – Without oral candidiasis
1 – Erythematous candidiasis carrier
2 – Pseudomembranous candidiasis carrier
The cd4 Cell Count was obtained by means of 
blood collection performed on the same day as the 
stomatological examination, and its results were af-
terwards noted on the patient’s case history record. 
The cd4 count levels were as follows:
With regard to the number of cd4 cells:
1 – Number of cd4 ≥ 500 cel/mm³
2 – 500 cel/mm³ > number of cd4 ≥ 200 cel/mm³
3 – Number of cd4 < 200 cel/mm³
The material was collected by a single examiner 
from the oral mucosa using a sterile swab and was 
seeded, close to the lamp flame, in Sabouraud dex-
trose agar (Difco, Detroit, IL, USA), in addition to 
100 µg/ml of Chloramphenicol (Park-Davis, São 
Paulo, SP, Brazil).
The plates were then incubated at 25°C for pos-
terior yeast isolation. In case of negativity, they were 
maintained during 30 days.
The samples were identified according to the 
identification protocol of the Micology Center, Mi-
crobiology Department, Biomedical Sciences Insti-
tute, University of São Paulo, which included:
Microculture on Slide (Corn-meal Agar in addi-
tion to Tween 80)
Research of germination tubes
Carbon hydrate fermentation test
Assimilation tests for carbon and nitrogen 
sources
Clinical record readings
The patients’ clinical records contained informa-
tion on which medication was used, on the results of 
the cd4 cell counts done on the day of collection, as 
well as on the patients that did not use any anti-HIV 
medication. 
The medication therapy administered to HIV vi-
rus carriers is very diversified. Generally, a combina-
tion of drugs (cocktail) is used. The presence or ab-
sence of proteinase inhibitor drugs was considered 
the delimitation for the groups setting. The drugs 
•
•
•
•
used at the time the patients’ records were read con-
sidering the delimitation factor of the groups were: 
indinavir (Merk Sharp Dohme, São Paulo, SP, Bra-
zil), nelfinavir (Roche, São Paulo, SP, Brazil), rito-
navir (Abott, São Paulo, SP, Brazil) and saquinavir 
(Roche, São Paulo, SP, Brazil).
Statistical analysis
Descriptive analysis was carried out for all the 
study variables. The Chi-square test was used for the 
qualitative variables. For the quantitative variables, the 
homogeneity of the variances was tested by the Levene 
Test, and the normality of the data, by the Kolmogo-
rov-Smirnov Test with the Lilliefors correction.
The variables that satisfied these two principles 
were submitted to parametric tests. In order to as-
sess any differences between the medication groups, 
Analysis of Variance (ANOVA) was used, and when 
this was statistically significant, the HSD -Tukey 
(Honest Significant Difference) test was used to as-
sess where the differences were.
Results
Of the 193 patients examined, 70.47% were men 
(136/193), with a mean age of 40 years, and 29.53% 
were women (57/193), with a mean age of 37 years. 
Analysis of the characteristics of the isolates en-
abled C. albicans to be identified in 47.67% (92/193) 
of the patients.
With regard to medication, the patients were di-
vided into 3 groups:
Group A – 111 patients using PI drugs.
Group B – 56 patients using NPI drugs.
Group C – 26 patients without medication. 
Table 1 shows the biodemographics related to 
gender and age of the medication groups. 
The distribution of C. albicans carriers per med-
ication group showed no statistically significant dif-
ferences (Table 2). 
In the clinical intraoral examination, 18.13% 
(35/193) of the patients presented clinical signs of 
candidiasis. The erythematous form was predomi-
nant, with 60% (21/35) of the cases, and the pseu-
domembranous form represented 40% (14/35) of 
the cases. The clinical features of candidiasis in each 
group are expressed in Table 3.
•
•
•
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The Cd4 cell counts showed no statistically sig-
nificant difference (ANOVA) among the studied 
groups (Table 4).
The clinical forms showed statistical differences 
related to Cd4 cell counts (p = 0.036, Table 5). The 
Pseudomembranous form presented smaller cell 
counts than the erythematous form (p = 0.037) and 
without lesions (P = 0.0167). The correlation be-
tween cd4 cell count and the isolation of C. albicans 
was statistically significant (p = 0.046 - t-test).
The relationship between the levels of cd4 cells 
and the clinical forms of candidiasis (Table 6) showed 
statistically significant differences (p = 0.029).
Discussion
Earlier studies on AIDS emphasized the preva-
lence of opportunistic infections, mainly oral can-
didiasis, in HIV-infected individuals, and observed 
that the clinical signs of oral candidiasis increased 
with the progression of the disease.3 Today, the re-
lated literature remains controversial about the rea-
sons for the high incidence of candidiasis in HIV+ 
Variable
Group A
N = 111
Group B
N = 56
Group C
N = 26
Test
Chi-square
χ22 = 1.462
p = 0.482
Gender
Male 82 (73.87) 37 (66.07) 17 (65.38)
Female 29 (26.13) 19 (33.93) 9 (34.62)
Age
µ ± SD 40.93 ± 9.65 38.46 ± 9.05 33.42 ± 7.39
ANOVA
p = 0.00093
Median 40.00 37.00 33.00
Min - Max 20 – 67 19 - 62 18 - 46
N = number of patients.
Table 1 - Biodemographics 
related to gender and age of the 
medication groups.
C. albicans
Group A
N = 111
Group B
N = 56
Group C
N = 26
Test
Chi-square
χ2 2 = 4.034
p = 0.133
Negative 62 (55.85) 25 (44.64) 14 (53.85)
Positive 49 (44.15) 31 (55.36) 12 (46.15)
N = number of patients.
Table 2 - Distribution of 
C. albicans carriers per 
medication group.
Clinical diagnosis
Group A
N = 111
Group B
N = 56
Group C
N = 26
Test
Chi-square
χ22 = 6.616
p = 0.158
Without oral 
candidiasis
93 (83.78) 46 (82.14) 19 (73.08)
Erythematous 
candidiasis 
12 (10.81)  7 (12.50)  2 (7.69)
Pseudomembranous 
candidiasis 
 6 (5.41)  3 (5.36)  5 (19.23)
N = number of patients.
Table 3 - Clinical features of 
candidiasis in each group.
Cd4
Group A
N = 111
Group B
N = 56
Group C
N = 26
Test
Anova
p = 0.28
µ ± SD 412.96 ± 291.14 431.61 ± 249.38 515.96 ± 384.18
Median 357.00 399.50 511.00
Min - Max 18 - 1,678 33 - 1,208 16 - 1,924
N = number of patients.
Table 4 - Cd4 cell counts of the 
medication groups.
Witzel AL, Silveira FRX, Pires MFC, Lotufo MA
Braz Oral Res 2008;22(4):371-7 375
patients. Many believed that an immune system de-
ficiency triggered by AIDS was responsible for the 
severity of oral candidiasis, and not the high viru-
lence of the yeast, since most studies had found no 
differences between the isolates from HIV-infected 
and non-infected individuals.17
The importance of candidiasis in AIDS patients 
led to the introduction of preventive protocols with 
antifungal drugs, mainly fluconazol. This may have 
been responsible for the selection of strains resistant 
to azolic derivatives.18 Another important fact is that 
the resistance to azolics presented by C. albicans is 
not evidenced in the same manner as in non-HIV 
patients.19
There are indications that the selection of more 
pathogenic strains is possible, and this possibility 
must not be neglected while caring for HIV+ patients 
infected with C. albicans. Certain strains of C. albi-
cans have a specific Ca3 repetitive sequence of DNA 
which is more frequent in individuals with AIDS 
when compared with samples isolated from individ-
uals that are non-carriers of the HIV virus.2
Characterization of the differences among strains 
isolated from HIV+ individuals and control groups 
began to increase in the 1990s. Virulence factors 
from C. albicans were shown to be more expressive 
in HIV-carrier individuals.20,21
The frequency of oral candidiasis in HIV+ pa-
tients varies among the different reports, and can af-
fect up to 94% of infected individuals. However, the 
prevalence of candidiasis in HIV+ individuals has di-
minished.22,23 The data of the present study corrobo-
rate this affirmation, as the incidence of candidiasis 
in the present study was 18.13%, which can be con-
sidered low when compared with the values of 80.1% 
found in the related literature.24 Many studies attri-
bute this reduction due to the use of protease inhibi-
tors for the treatment of patients with AIDS.9,13,25,26
The present study was unable to make this cor-
relation, since the incidence of 18.13% of oral 
candidiasis, although low, did not present statisti-
cally significant differences between the medication 
groups (p = 0.158). It was expected that the pa-
tients in Group A (n = 49/111), who used PI drugs, 
would present a lower incidence in comparison with 
that of the other groups. PI also had no influence 
on the frequency of C. albicans isolates. When the 
cd4 cell count was correlated with the isolation of 
C. albicans, a statistically significant difference was 
observed between the group of colonized patients, 
who had a lower cd4 cell count, and the group with-
out isolation (p = 0.046).
The relationship between PI drugs and a de-
creased frequency of oral candidiasis is credited by 
many authors to a direct action of the PI drugs on 
the yeast.3,16,27
The antifungal effect of the PI indinavir and sa-
quinavir was demonstrated, in vitro and in vivo, at 
Cd4
Without oral 
candidiasis
N = 158
Erythematous 
candidiasis 
N = 21
Pseudomembranous 
candidiasis 
N = 14
Test
ANOVA
p = 0.036
µ ± SD 451.32 ± 306.21 416.33 ± 214.58 240.93 ± 184.14
Median 399.00 368.00 174.00
Min – Max 16 - 1,924 131 - 818 20 - 542
N = number of patients.
Table 5 - Relationship between 
clinical forms of candidiasis 
and Cd4 cell counts.
Cd4
Without oral 
candidiasis
N = 158
Erythematous 
candidiasis 
N = 21
Pseudomembranous 
candidiasis 
N = 14
Test
Chi-square
χ24= 10.819
p = 0.029
1 56 (35.44) 8 (38.10) 2 (14.29)
2 71 (44.94) 9 (42.86) 4 (28.57)
3 31 (19.62) 4 (19.05) 8 (57.14)
N = number of patients.
Table 6 - Levels of Cd4 cells 
and the clinical forms of 
candidiasis.
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a minimum inhibitory concentration much higher 
than that attained during the conventional treat-
ments using these drugs.10
Therapy with PI drugs has influenced not only 
the prevalence of oral candidiasis, but the indexes 
of other pathosis have also been diminished,1,12,28 in 
which the pathogen was not directly inhibited by the 
PI. This led the authors to believe that restoration of 
the HIV+ patient’s immune system provided by the 
PI is the most relevant fact to be considered, during 
the course of treatment.
The cd4+ T lymphocyte counts showed no statis-
tically significant differences among the medication 
groups. However, when the presence of candidiasis 
and its different clinical forms was assessed (Ta-
ble 5), it was found that patients with pseudomem-
branous candidiasis presented a lower cd4 count in 
comparison with patients that had the erythematous 
form, and patients without candidiasis (p = 0.036), 
evidencing the importance of the immune response 
with regard to this illness.
Conclusions
The frequencies of C. albicans isolates in the oral 
mucosa of the evaluated patients were statistical-
ly similar for the 3 medication groups.
Cd4 values were significantly lower in patients 
who were C. albicans carriers.
The frequencies of oral lesions compatible with 
candidiasis did not differ statistically among the 
medication groups.
The cd4 cell counts were similar for the different 
medication groups.
The cd4 cell values of the patients with pseudo-
membranous candidiasis were lower when com-
pared with those of patients without lesions and 
with erythematous lesions.
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